Cargando…

The role of combination therapy in managing pulmonary arterial hypertension

Pulmonary arterial hypertension (PAH) is a complex, progressive disease with several pathobiological mechanisms, including the endothelin, nitric oxide and prostacyclin pathways. Current treatments for PAH target one of these pathways and, in more severe cases or instances of disease worsening, may...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghofrani, Hossein-Ardeschir, Humbert, Marc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2014
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487405/ https://www.ncbi.nlm.nih.gov/pubmed/25445945 http://dx.doi.org/10.1183/09059180.00007314

Ejemplares similares

The molecular targets of approved treatments for pulmonary arterial hypertension
por: Humbert, Marc, et al.
Publicado: (2016)

New horizons in pulmonary arterial hypertension therapies
por: Galiè, Nazzareno, et al.
Publicado: (2013)

Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Humbert, Marc, et al.
Publicado: (2019)

Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies)
por: Ghofrani, Hossein-Ardeschir, et al.
Publicado: (2020)

Medical management of chronic thromboembolic pulmonary hypertension
por: Pepke-Zaba, Joanna, et al.
Publicado: (2017)

Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension
por: Lang, Irene, et al.
Publicado: (2017)

Quality of life in patients with chronic thromboembolic pulmonary hypertension
por: Mathai, Stephen C., et al.
Publicado: (2016)

Riociguat for pulmonary arterial hypertension associated with congenital heart disease
por: Rosenkranz, Stephan, et al.
Publicado: (2015)

Thin Air Resulting in High Pressure: Mountain Sickness and Hypoxia-Induced Pulmonary Hypertension
por: Grimminger, Jan, et al.
Publicado: (2017)

Switching inhaled iloprost formulations in patients with pulmonary arterial hypertension: the VENTASWITCH Trial
por: Richter, Manuel J., et al.
Publicado: (2018)

Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2
por: Humbert, Marc, et al.
Publicado: (2017)

Risk assessment in pulmonary arterial hypertension
por: Raina, Amresh, et al.
Publicado: (2016)

Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension
por: White, R. James, et al.
Publicado: (2019)

Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies
por: Cartin-Ceba, Rodrigo, et al.
Publicado: (2018)

Pulmonary Hypertension in Acute and Chronic High Altitude Maladaptation Disorders
por: Sydykov, Akylbek, et al.
Publicado: (2021)

Analysis of Electrocardiographic Criteria of Right Ventricular Hypertrophy in Patients with Chronic Thromboembolic Pulmonary Hypertension before and after Balloon Pulmonary Angioplasty
por: Ley, Lukas, et al.
Publicado: (2023)

Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension
por: Humbert, Marc, et al.
Publicado: (2023)

Reply to Bogaard et al.: Emphysema Is—at the Most—Only a Mild Phenotype in the Sugen/Hypoxia Rat Model of Pulmonary Arterial Hypertension
por: Kojonazarov, Baktybek, et al.
Publicado: (2019)

Mechanisms of disease: pulmonary arterial hypertension
por: Schermuly, Ralph T., et al.
Publicado: (2011)

Targeting peptidyl-prolyl isomerase 1 in experimental pulmonary arterial hypertension
por: Rai, Nabham, et al.
Publicado: (2022)

Anxiety and depression disorders in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Harzheim, Dominik, et al.
Publicado: (2013)

Effects of riociguat in severe experimental pulmonary hypertension
por: Kojonazarov, Baktybek, et al.
Publicado: (2011)

Role of Store-Operated Ca(2+) Entry in the Pulmonary Vascular Remodeling Occurring in Pulmonary Arterial Hypertension
por: Masson, Bastien, et al.
Publicado: (2021)

Pathobiology of pulmonary arterial hypertension: understanding the roads less travelled
por: Hemnes, Anna R., et al.
Publicado: (2017)

Riociguat for pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD): A subgroup analysis from the PATENT studies
por: Stephan, Rosenkranz, et al.
Publicado: (2015)

Glycogen Synthase Kinase 3beta Contributes to Proliferation of Arterial Smooth Muscle Cells in Pulmonary Hypertension
por: Sklepkiewicz, Piotr, et al.
Publicado: (2011)

Pulmonary arterial hypertension
por: Montani, David, et al.
Publicado: (2013)

Screening for pulmonary arterial hypertension in systemic sclerosis
por: Weatherald, Jason, et al.
Publicado: (2019)

Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study
por: Coghlan, J. Gerry, et al.
Publicado: (2018)

Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study
por: Rhodes, Christopher J, et al.
Publicado: (2017)

Incidence and prognostic significance of malignant arrhythmias during (repetitive) Holter electrocardiograms in patients with pulmonary hypertension
por: Bandorski, Dirk, et al.
Publicado: (2023)

Chronic thromboembolic pulmonary hypertension
por: Kim, Nick H., et al.
Publicado: (2019)

Illuminating the Importance of Pulmonary Arterial Compliance in Pulmonary Hypertension
por: Weatherald, Jason, et al.
Publicado: (2023)

Targeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension
por: Weiss, Astrid, et al.
Publicado: (2019)

Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)
por: Marra, Alberto M., et al.
Publicado: (2018)

Profiles and treatment patterns of patients with pulmonary arterial hypertension on monotherapy at experienced centres
por: Wissmüller, Max, et al.
Publicado: (2022)

Pulmonary Arterial Hypertension: Combination Therapy in Practice
por: Burks, Marsha, et al.
Publicado: (2018)

Prostanoid therapies in the management of pulmonary arterial hypertension
por: LeVarge, Barbara L
Publicado: (2015)

Smouldering fire or conflagration? An illustrated update on the concept of inflammation in pulmonary arterial hypertension
por: Perros, Frédéric, et al.
Publicado: (2021)

Implication of Potassium Channels in the Pathophysiology of Pulmonary Arterial Hypertension
por: Le Ribeuz, Hélène, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gjrlknudc7uthcpu036dr4u7pt